News

The 5-ht6 antagonist failed to meet its primary efficacy endpoints in the phase 2b HEADWAY and pilot phase 2 Gait and Balance studies. In the HEADWAY trial, intepirdine

UK Biobank aims to enhance the prevention, diagnosis and treatment of a range of severe illnesses including heart diseases, stroke, diabetes, cancer, arthritis, osteoporosis, eye disorders, depression and forms

The role of BRUDAC is to provide recommendations to the FDA. The FDA decision on whether or not to approve the TLANDO New Drug Application (“NDA”) is anticipated

Baxter will assume other expenses, including contingent liabilities associated with PREVELEAK. Baxter is a global medical products company that is committed to advancing surgical innovation with a variety

This Breakthrough Therapy Designation is supported by positive Phase 2b results previously announced in September 2017,11 and marks 13 Breakthrough Therapy Designations granted to AbbVie's investigational treatments since

The board of Ablynx said that in the interests of all its stakeholders, it has come to a unanimous conclusion that the proposal also undervalues its future prospects

 The approval is based on data from the pivotal Phase 3 '482 study, the largest international multiple myeloma clinical trial ever conducted, which enrolled 1,718 patients. "Up to

In collaboration with Liverpool John Moores University and AstraZeneca, the team have developed a simple approach to trawl through large databases of pharmaceutical drugs and assess the likely

The deal is structured in three parts, with Celgene paying $1.1bn in cash upfront for Impact Biomedicines, which is currently engaged in the development of fedratinib for the treatment